BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pfizer Inc. (PFE) Taps Execs for Animal Health Spin Off


10/12/2012 7:54:55 AM

Pfizer Inc. PFE has named nine executives to round out the leadership team for its planned animal-health spinoff, Zoetis. In a filing with the U.S. Securities and Exchange Commission on Thursday, Pfizer said the executive vice presidents were named this month to lead various geographic regions, research and development, and other areas for Zoetis. All have been with Pfizer for at least several years. Pfizer earlier this year named Juan Ramon Alaix as chief executive of Zoetis, as well as a chief financial officer and board of directors. New York-based Pfizer plans an initial public offering for up to a 20% ownership stake in Zoetis, and may pursue the separation of the remaining 80% stake at a later date. Pfizer expects to complete the IPO in the first half of 2013. The Zoetis IPO is part of Pfizer's plan to shed certain businesses and hone its focus on human pharmaceuticals, partially unwinding years of mega-mergers that made Pfizer the largest drug maker in the world by sales. Pfizer previously agreed to sell its nutrition unit to Nestle SA (NESN.VX, NSRGY) for $11.85 billion in cash.

Read at Market Watch

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES